BR112022007721A2 - Método para o tratamento da demência - Google Patents
Método para o tratamento da demênciaInfo
- Publication number
- BR112022007721A2 BR112022007721A2 BR112022007721A BR112022007721A BR112022007721A2 BR 112022007721 A2 BR112022007721 A2 BR 112022007721A2 BR 112022007721 A BR112022007721 A BR 112022007721A BR 112022007721 A BR112022007721 A BR 112022007721A BR 112022007721 A2 BR112022007721 A2 BR 112022007721A2
- Authority
- BR
- Brazil
- Prior art keywords
- dementia
- treatment
- semaglutide
- glp
- subjects
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 229950011186 semaglutide Drugs 0.000 abstract 1
- 108010060325 semaglutide Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007721A2 true BR112022007721A2 (pt) | 2022-07-12 |
Family
ID=73172681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007721A BR112022007721A2 (pt) | 2019-11-06 | 2020-11-05 | Método para o tratamento da demência |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
| CN118510545A (zh) | 2021-12-02 | 2024-08-16 | 哥本哈根大学 | 用于治疗神经退行性疾病的肽-药物缀合物 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| WO2026096637A1 (en) * | 2024-10-30 | 2026-05-07 | Tiziana Life Sciences Plc | Glp-1 agonists and foralumab combination therapies |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| US8756102B2 (en) * | 2009-11-06 | 2014-06-17 | Edatanetworks Inc. | Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| AU2016379403B2 (en) * | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
-
2020
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
- 2020-11-06 TW TW114103408A patent/TWI923289B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| TW202519256A (zh) | 2025-05-16 |
| ES2984177T3 (es) | 2024-10-29 |
| MA57599B1 (fr) | 2024-06-28 |
| MX2022004779A (es) | 2022-06-14 |
| TWI923289B (zh) | 2026-04-21 |
| JP2023500032A (ja) | 2023-01-04 |
| IL291876A (en) | 2022-06-01 |
| EP4054620C0 (en) | 2024-05-29 |
| KR20220110731A (ko) | 2022-08-09 |
| PL4054620T3 (pl) | 2024-10-14 |
| CA3154744A1 (en) | 2021-05-14 |
| EP4414031A2 (en) | 2024-08-14 |
| TW202118509A (zh) | 2021-05-16 |
| US20220280612A1 (en) | 2022-09-08 |
| EP4054620B1 (en) | 2024-05-29 |
| US12539326B2 (en) | 2026-02-03 |
| US20240207364A1 (en) | 2024-06-27 |
| TWI890704B (zh) | 2025-07-21 |
| HRP20241052T1 (hr) | 2024-11-08 |
| US20250099549A1 (en) | 2025-03-27 |
| JP7670698B2 (ja) | 2025-04-30 |
| PH12022550842A1 (en) | 2023-10-09 |
| CN114728042A (zh) | 2022-07-08 |
| US20230302094A1 (en) | 2023-09-28 |
| AU2020377469A1 (en) | 2022-04-28 |
| HUE067514T2 (hu) | 2024-10-28 |
| JP2025027130A (ja) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550842A1 (en) | Glp-1 receptor agonists in dementia | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| BR112018005114A2 (pt) | um novo polipeptídeo de endolisina | |
| MX2019006429A (es) | Compuestos novedosos como agonistas peptidicos trigonales de los receptores de glp1/glucagon/gip. | |
| BR112018014281A2 (pt) | agentes, usos e métodos para o tratamento da sinucleinopatia | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JOP20200231B1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| SA519401933B1 (ar) | تركيبات صيدلية تحتوي على الأنسولين | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
| CO2020008863A2 (es) | Biomarcadores de tolerancia inmunitaria inducida por metotrexato | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| CL2020001131A1 (es) | Administración oral de análogos del péptido glp-1. | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| WO2020009740A3 (en) | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders | |
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico |